Payment overview · 2025
General Payments
$121,830.06
285 reported records · 15 companies
Healthcare provider profile · identity verified
Jasvindar Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAINT LOUIS, MO · NPI 1811931264
Verified facts
What the public records show
CMS Open Payments records show Jasvindar Singh, MD received $121,830.06 in general payments during 2025 across 285 reported records.
Philips North America LLC accounted for 86.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $104,738.94 | 86.0% | 185 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $4,789.49 | 3.9% | 8 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $4,635.43 | 3.8% | 19 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,656.62 | 2.2% | 30 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,080.39 | 1.7% | 9 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $643.29 | 0.5% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $576.17 | 0.5% | 6 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $547.98 | 0.5% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $514.82 | 0.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $192.76 | 0.2% | 1 | 2025 |
| Avantec Vascular Corporation | Unresolved — no canonical attribution shown | $107.96 | 0.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $101.11 | 0.1% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $100.00 | 0.1% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $80.89 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.21 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $43,838.59 | 54 |
| Consulting Fee | $32,250.00 | 7 |
| Honoraria | $22,500.00 | 7 |
| Food and Beverage | $19,241.47 | 216 |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $37,081.05 | 26 | 2025 |
Source payment records
|
|||||
| US EQ Undivided Normalized: us eq undivided |
Device | Philips North America LLC | $22,500.00 | 7 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $17,819.50 | 95 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $15,618.92 | 7 | 2025 |
Source payment records
|
|||||
| Azurion 7 B12 Normalized: azurion 7 b12 |
Device | Philips North America LLC | $6,699.91 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $4,635.43 | 19 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $2,340.59 | 25 | 2025 |
Source payment records
|
|||||
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $2,138.91 | 21 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,080.39 | 9 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $643.29 | 7 | 2025 |
Source payment records
|
|||||
| INeb Devices Normalized: ineb devices |
Device | Philips North America LLC | $631.22 | 6 | 2025 |
Source payment records
|
|||||
| ELCA Normalized: elca |
Device | Philips North America LLC | $436.56 | 4 | 2025 |
Source payment records
|
|||||
| Eagle Eye Normalized: eagle eye |
Device | Philips North America LLC | $433.40 | 4 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $397.12 | 4 | 2025 |
Source payment records
|
|||||
| Specialty Tempus IC Monitor Normalized: specialty tempus ic monitor |
Device | Philips North America LLC | $367.75 | 4 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $292.02 | 4 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $275.12 | 4 | 2025 |
Source payment records
|
|||||
| IGT FS Serv Undivided Normalized: igt fs serv undivided |
Device | Philips North America LLC | $265.45 | 1 | 2025 |
Source payment records
|
|||||
| Intrasight Integrated Normalized: intrasight integrated |
Device | Philips North America LLC | $208.15 | 2 | 2025 |
Source payment records
|
|||||
| NHancer Rx Normalized: nhancer rx |
Device | BIOTRONIK INC. | $205.48 | 1 | 2025 |
Source payment records
|
|||||
| Oscar Normalized: oscar |
Device | BIOTRONIK INC. | $205.48 | 1 | 2025 |
Source payment records
|
|||||
| ReCross Normalized: recross |
Device | BIOTRONIK INC. | $205.48 | 1 | 2025 |
Source payment records
|
|||||
| TrapIT Normalized: trapit |
Device | BIOTRONIK INC. | $205.48 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $192.76 | 1 | 2025 |
Source payment records
|
|||||
| Orsiro Mission Normalized: orsiro mission |
Device | BIOTRONIK INC. | $171.23 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $160.42 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $152.88 | 1 | 2025 |
Source payment records
|
|||||
| Azurion 7 M20 Normalized: azurion 7 m20 |
Device | Philips North America LLC | $136.37 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $131.27 | 1 | 2025 |
Source payment records
|
|||||
| RADIAL 360 Normalized: radial 360 |
Device | CORDIS US CORP. | $127.72 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $80.89 | 1 | 2025 |
Source payment records
|
|||||
| Laser CVX300 Normalized: laser cvx300 |
Device | Philips North America LLC | $77.67 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $50.66 | 1 | 2025 |
Source payment records
|
|||||
| AngioSculpt CV RX Normalized: angiosculpt cv rx |
Device | Philips North America LLC | $41.99 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $40.91 | 1 | 2025 |
Source payment records
|
|||||
| Omniwire Normalized: omniwire |
Device | Philips North America LLC | $40.01 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $31.00 | 1 | 2025 |
Source payment records
|
|||||
| BRITE TIP RADIANZ Normalized: brite tip radianz |
Device | CORDIS US CORP. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121,830.06 · 285 records | Philips North America LLC | AVVIGO Guidance System, AngioSculpt CV RX, Azurion 7 B12, Azurion 7 M20, BRITE TIP RADIANZ, COREVALVE EVOLUT R, Coronary Other, Coronary Undivided, DRAGONFLY OPSTAR, ECC Solutions, ELCA, Eagle Eye, FFRct, General - Therapies, IGT Devices Systems Undivided, IGT Devices Undivided, IGT FS Serv Undivided, INeb Devices, Indigo System, Intrasight Integrated, Labosys, Laser CVX300, MYNX CONTROL VENOUS, NHancer Rx, ONYX FRONTIER, Omniwire, Orsiro Mission, Oscar, Paradise Ultrasound Renal Denervation System, Peripheral Vascular Undivided, RADIAL 360, REPATHA, ROTAPRO, ReCross, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Specialty Tempus IC Monitor, TrapIT, US EQ Undivided | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error